Oppenheimer analyst Hartaj Singh maintained a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.92.
Singh covers the Healthcare sector, focusing on stocks such as Moderna, Regeneron, and Gilead Sciences. According to TipRanks, Singh has an average return of 10.9% and a 43.99% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pharming Group with a $38.50 average price target, implying a 252.56% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $37.00 price target.
See the top stocks recommended by analysts >>
PHAR market cap is currently $774M and has a P/E ratio of -32.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group (PHAR) Company Description:
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue generated from the United States.
